alexa

GET THE APP

Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India | OMICS International | Abstract
ISSN: 1522-4821

International Journal of Emergency Mental Health and Human Resilience
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India

Mansoor Ahmad Dar, MD1, Rayees Ahmad Wani, MD1, Mushtaq Ahmad Margoob, MD1, InInaamul Haq, MD2, Arshad Hussain, MD1, Rajesh Kumar Chandel, MD1*, Yasir Hassan Rather, MD1, MajidShafi Shah, MD1, Altaf Ahmad Malla, MD1

1Department of Psychiatry, Government Medical College, Srinagar, J & K, India

2Department of Community Medicine, Government Medical College, Srinagar, J & K, India

*Corresponding Author:
Rajesh Kumar Chandel, MD
E-mail: [email protected]

Abstract

Background: About 60% patients with major depressive disorder do not achieve a sufficient response to standard antidepressant therapy and about two-thirds of patients receiving initial antidepressant medication do not achieve remission. Various strategies are being employed to counter this problem. Studies have shown that atypical antipsychotics, augmented to antidepressants for major depressive disorder patients, produced higher response and remission rates. The data regarding the augmentation of antidepressants with amisulpride is very scarce as compared to other atypical antipsychotics.

Objective: To evaluate whether augmentation with amisulpride is effective and tolerable in patients of major depressive disorder (MDD) who did not respond significantly to adequate trials of standard antidepressants.

Methodology and Results: In our open label 6 weeks study, amisulpride was added to baseline antidepressant medication of treatment resistant patients of major depressive disorder. A total of 112 patients enrolled in the study with a mean age of 39.37 years out of which 83% completed the study. Over a period of 6 weeks, 71% patient showed response and 40% patient remitted (p<0.001) with a mean amisulpride dose of 135.31 mg/day. The mean decrease in HAM-D17 score was 16.17 points. There was more than 2 point change in mean CGI-S score from base line to endpoint. Common adverse effects were akathisia (4.64%), sleep disturbances (10.71%), restlessness (5.36%) and extrapyramydial side-effects (4.64%).

Conclusion: Augmentation of antidepressant drugs with low doses of amisulpride seems to be effective and tolerable in patients of major depressive disorder who do not respond adequately to standard antidepressant medications.

Keywords

Google scholar citation report
Citations : 1498

International Journal of Emergency Mental Health and Human Resilience received 1498 citations as per google scholar report

International Journal of Emergency Mental Health and Human Resilience peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • Academic Keys
  • ResearchBible
  • CiteFactor
  • Cosmos IF
  • CINAHL Complete
  • Scimago
  • British Library
  • SCOPUS
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • World Catalogue of Scientific Journals
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • University Of Baltimore
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • University of Lincoln
Share This Page
Top